Dignity Health St. J
Dignity Health St. Joseph’s Hospital and Medical Center launches new initiative to address health disparities of African Americans with chronic kidney disease
February 27, 2023 16:08 ET | Dignity Health St. Joseph's Hospital and Medical Center
PHOENIX, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Dignity Health St. Joseph’s Hospital and Medical Center has launched a new initiative to address race-based algorithms in early diagnosis of chronic kidney...
Global Liquid Biopsy Market
Liquid Biopsy Global Market Report 2022: Increased Government Funding for Cancer Detection Drives Growth
November 15, 2022 08:33 ET | Research and Markets
Dublin, Nov. 15, 2022 (GLOBE NEWSWIRE) -- The "Liquid Biopsy Global Market Report 2022, By Product, By End User, By Clinical Application" report has been added to ResearchAndMarkets.com's offering....
CO-MasterLogo@4x_300 DPI.png
Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients
December 16, 2021 06:30 ET | Cullinan Oncology, Inc.
CLN-081 continues to demonstrate a differentiated clinical profile at the recommended Phase 2 dose of 100mg BID Continued high response rate with favorable safety and tolerability profile observed in...
CO-MasterLogo@4x_300 DPI.png
Cullinan Oncology to Provide Clinical Update for CLN-081 in NSCLC EGFR Exon 20 Patients
December 13, 2021 07:00 ET | Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology therapies,...
Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China
November 09, 2021 08:00 ET | Zai Lab Limited; Blueprint Medicines
-- Zai Lab obtains exclusive rights to develop and commercialize BLU-945 and BLU-701 in Greater China -- -- Collaboration accelerates and expands global development of Blueprint Medicines’...
Sorrento Enters Into Binding Term Sheet to Acquire Exclusive Rights to Abivertinib with Completed Registrational Trial Data in Non-Small Cell Lung Cancer
May 21, 2020 07:00 ET | Sorrento Therapeutics, Inc.
Novel TKI compound with dual selective targeting of mutant forms of EGFR and BTKMore than 600 patients have been treated with the compound across studies, with over 200 patients in the completed...
PRPO logo.png
Continued ICP Orders From Japanese Customers
March 05, 2019 07:40 ET | Precipio, Inc.
NEW HAVEN, Conn., March 05, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it continues to receive both new and repeat business from...
PRPO logo.png
Precipio ICE COLD-PCR™ Technology Selected by the University of Cincinnati Medical Center for Liquid Biopsy Study
November 27, 2018 09:38 ET | Precipio, Inc.
NEW HAVEN, Conn., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that its ICE COLD-PCR™ (ICP) technology has been selected for a...
PRPO logo.png
Precipio Expands ICE-COLD PCR™ Lung Cancer Mutation Detection Offering
September 20, 2018 07:37 ET | Precipio, Inc.
New kit examines most relevant EGFR exons that impact therapeutic decisions for lung cancer patients NEW HAVEN, Conn., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Precipio, Inc. (NASDAQ: PRPO), announced...
PRPO logo.png
Precipio Launches Unique Lung Cancer Monitoring Test for Therapy Resistance
February 15, 2018 08:38 ET | Precipio, Inc.
NEW HAVEN, Conn., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Precipio, Inc. (NASDAQ:PRPO) announced today its launch of the first lung cancer treatment resistance panel specifically for the critical...